Anne-Marie Duliege, M.D.

An executive officer of a Commercial Life Science Entity

Appointed by the Controller

Dr. Duliege is a senior executive (EVP, Chief Medical Officer, Head of Research & Clinical Development) with over 20 years of experience in the pharmaceutical industry.  She is currently at ChemoCentryx, Inc., as EVP, chief of strategic development and head of immuno-oncology.

Prior to joining ChemoCentryx in 2014, Dr. Duliege was Chief Medical Officer and Head of Research & Clinical Development at Affymax Inc., where her responsibilities included all clinical and non-clinical research.  She also helped set company strategies, contributed to investor relations and supported business development activities.  Under Dr. Duliege’s leadership, her team completed an extensive development program and obtained FDA approval of the company’s lead product, Omontys.  Before 2007, Dr. Duliege served as Vice President of Clinical, Regulatory and Medical Affairs.  She joined Affymax in 2004, and was instrumental in raising capital and taking the company public.  Prior to joining Affymax, Dr. Duliege was a Senior Medical Director at Chiron Corporation where she built a record of significant clinical accomplishments in executing Phase I through IV studies in pulmonary medicine, infectious diseases and immunology.  Before Chiron, Dr. Duliege was a Senior Research Physician at Genentech Inc., working on HIV vaccine and treatment.  Prior to her career in the pharmaceutical industry, Dr. Duliege was an Epidemiologist with the National Institute of Science and Medical Research in Paris.

Dr. Duliege received her M.D. degree and certification in Pediatrics from Paris Medical School, an M.S. in Epidemiology from the Harvard School of Public Health, and an M.S. in Biostatistics from Paris Medical School.  She continues to practice medicine as an Adjunct Clinical Assistant Professor at Stanford’s School of Medicine and the Lucile Packard Children’s Hospital.  In 2012, she was appointed by the California State Controller to serve on the board of CIRM, the California Institute for Regenerative Medicine (stem cell research).  She also serves on the board of BayBio and on the boards of nonprofit organizations focused on the prevention of HIV.  She is personally committed to supporting public health efforts in developing countries